The IFIH1 gene encodes MDA5, a key sensor in the innate immune system that detects viral double-stranded RNA and triggers antiviral defenses through interferon production.
Changes in IFIH1 can either heighten inflammation, leading to autoimmune and inflammatory diseases, or weaken viral defenses, resulting in severe infections.
The IFIH1 gene gives instructions for making a cytoplasmic protein called MDA5 (melanoma differentiation-associated protein 5). MDA5 is part of the body's first line of immune defense, called the innate immune system.
MDA5 works like an alarm system inside cells. It detects double-stranded RNA (dsRNA)—a type of genetic material viruses often make when infecting our cells.
Once MDA5 senses this RNA, it triggers a chain reaction that tells the body to produce interferons—proteins that stop viruses from spreading and help alert the immune system to fight back.
IFIH1 genetic testing is not a routine test; instead, it may be considered in the following scenarios:
Genetic testing of IFIH1 is not commonly done in everyday medical care. However, it can be helpful in special cases, especially in research or clinical assessment for certain rare conditions.
Research shows that changes in the IFIH1 gene are linked to diseases where the immune system attacks the body, such as:
In rare cases, IFIH1 testing may help explain why a person gets severe viral infections, especially in early life.
Testing is sometimes done when a patient has signs of rare inflammatory diseases involving the brain, skin, bones, or blood vessels.
Testing for IFIH1 is performed as a genetic test to look for mutations in the gene that would alter functional protein availability. The following section outlines the testing procedures and interpretation.
Genetic testing involves blood, saliva, or cheek swab samples, although specialized laboratories may recommend different sample types.
A cheek swab or saliva sample is easily obtained from the comfort of home, while blood samples typically require a blood draw.
Normal reference ranges for IFIH1 genetic testing are considered to be without mutations that can alter the activity of the IFIH1 proteins.
Depending on the scenario, genetic mutations can have different effects:
Some people have genetic mutations that make MDA5 overactive. This leads to too many interferons, which causes chronic inflammation, even when there's no infection.
Conditions linked to this include:
Aicardi-Goutières Syndrome is a rare disease characterized by brain inflammation, calcium buildup, and skin or immune system problems.
Singleton-Merten Syndrome causes calcification in the heart and blood vessels, dental abnormalities, and bone problems.
These disorders are sometimes called interferonopathies, because they involve too much interferon signaling. Some people with these genetic mutations show overlapping symptoms of both syndromes, which suggests a disease spectrum.
Other people have mutations that make MDA5 unable to detect viruses. These people may get frequent, severe viral infections, especially in the lungs and airways (like from RSV, flu, or rhinovirus).
This rare condition is called MDA5 deficiency and usually appears in infants or young children.
More common gene changes, called polymorphisms, can slightly change how active MDA5 is.
More active versions are linked to a higher risk of autoimmune diseases (like type 1 diabetes or lupus).
Less active versions may lower the risk of these conditions, but might slightly increase the risk of infections.
Not having these specific gene changes doesn’t mean the immune system works perfectly. Many other genes and environmental factors affect how our immune system responds to viruses or autoimmune triggers. IFIH1 is just one piece of a much larger puzzle.
Click here to compare genetic test panels and order genetic testing for health-related SNPs.
Aicardi-Goutières syndrome: MedlinePlus Genetics. (n.d.). Medlineplus.gov. https://medlineplus.gov/genetics/condition/aicardi-goutieres-syndrome/
Entry - *606951 - INTERFERON-INDUCED HELICASE C DOMAIN-CONTAINING PROTEIN 1; IFIH1 - OMIM. (2017). Omim.org. https://omim.org/entry/606951
Fumagalli, M., Cagliani, R., Riva, S., Pozzoli, U., Biasin, M., Piacentini, L., Comi, G. P., Bresolin, N., Clerici, M., & Sironi, M. (2010). Population Genetics of IFIH1: Ancient Population Structure, Local Selection, and Implications for Susceptibility to Type 1 Diabetes. Molecular Biology and Evolution, 27(11), 2555–2566. https://doi.org/10.1093/molbev/msq141
Gene Database. (2025). IFIH1 Gene - GeneCards | IFIH1 Protein | IFIH1 Antibody. Genecards.org. https://www.genecards.org/cgi-bin/carddisp.pl?gene=IFIH1
IFIH1 gene: MedlinePlus Genetics. (n.d.). Medlineplus.gov. https://medlineplus.gov/genetics/gene/ifih1/
IFIH1 interferon induced with helicase C domain 1 [Homo sapiens (human)] - Gene - NCBI. (2025). Nih.gov. https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=64135
MDA5 deficiency: MedlinePlus Genetics. (n.d.). Medlineplus.gov. https://medlineplus.gov/genetics/condition/mda5-deficiency/
Nassef, S. (2018). Evaluation of Impact of Interferon-Induced Helicase C Domain-Containing Protein 1 Gene in Egyptian Systemic Lupus Erythematosus Patients and its Relationship With Vascular Manifestations of the Disease. Archives of Rheumatology, 33(2), 181–189. https://doi.org/10.5606/archrheumatol.2018.6476
Singleton-Merten Syndrome. (2023, November 20). National Organization for Rare Disorders. https://rarediseases.org/rare-diseases/singleton-merten-syndrome/